Novacyt: on these numbers, the cheapest stock on the market
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the future?
Novacyt (EURONEXT GROWTH: ALNOV; LON: NCYT ), the clinical diagnostics specialist and superstar performer from 2020, updated on trading for the year ending 31 December 2020. Here are the astonishing highlights from an incredible year: Revenue +2400% to €311.6m (£277.0m) including revenue in the second half of the year of €239.2m (£213.7m). EBITDA profitability above €210m (£187m), representing an EBITDA margin of more than 67%, after adding 124 people to the payroll. Cash at 31 December 2020 was €101m (£89m), after significant investment in working capital and £10mspent on an acquisition. Remember to use our AIMsearch tool here to check whether…